BioCentury
ARTICLE | Company News

Archemix, Dicerna, miRagen deal

July 27, 2009 7:00 AM UTC

Archemix announced a pair of deals to use its aptamers to facilitate intracellular delivery of RNA-based therapeutics. Archemix and miRagen will develop conjugated aptamer-miRNA. miRagen has an option to negotiate for exclusive rights to develop and commercialize resulting therapeutics. Further terms were not disclosed. ...